Centers for Disease Control and Prevention a Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease | RFA CK 14 00504CONT17

Opportunity Information: Apply for RFA CK 14 00504CONT17

This opportunity is a continuation cooperative agreement from the Centers for Disease Control and Prevention (CDC) focused on a Creutzfeldt-Jakob Disease (CJD) lookback study, specifically aimed at assessing the risk of blood-borne transmission of the classic forms of CJD. In practical terms, the grant supports ongoing public health work that traces back potential exposure pathways involving blood and blood products, with the goal of better understanding whether and how classic CJD might be transmitted through transfusion or related blood-derived routes. Because CJD is a rare but fatal neurodegenerative prion disease, even a low-probability transmission risk has serious implications for blood safety policy, donor screening practices, and surveillance strategies. The emphasis on a "lookback" design signals that the work involves retrospective investigation, typically linking diagnosed CJD cases to prior donation or transfusion histories, then following the chain of potentially exposed recipients or donors to evaluate outcomes and identify any evidence consistent with transmission.

The funding mechanism is a cooperative agreement, which generally means CDC expects to be substantially involved in the funded activities rather than acting only as a pass-through funder. Cooperative agreements often involve collaboration on study design refinements, data elements, case definitions, analytic approaches, and coordination with national surveillance or laboratory resources. The activity category is Health, and the listing references CFDA number 93.084, which corresponds to CDC public health programs and underscores that this is fundamentally a public health surveillance and risk assessment effort rather than a purely academic research grant. The opportunity is labeled as continuation funding, reinforcing that it is meant to sustain an existing project or network rather than establish a new, open competition for first-time applicants.

Eligibility is narrowly restricted: only organizations that were previously awarded funding under the original announcement, RFA-CK-14-005, are eligible to receive this continuation award. That restriction is explicit and central to the notice. It means new applicants who were not part of the prior award cohort cannot apply, and the continuation is intended to maintain momentum, preserve specialized expertise, and ensure continuity of long-running follow-up that can be essential for rare disease investigations. The expected number of awards is listed as 10, indicating CDC anticipated supporting up to ten continuing entities under this continuation action, likely reflecting the number of prior recipients or the structure of the existing multi-site effort.

Key administrative details include the funding opportunity number RFA CK 14 00504CONT17, which indicates it is a continuation associated with the 2014 CJD lookback initiative, with the continuation notice posted in 2017. The original closing date for this continuation action is April 14, 2017, and the creation date is February 8, 2017. The award ceiling is listed as 0, which typically signals that a specific cap was not provided in the public synopsis or that the ceiling is determined through other budget guidance tied to the continuation awards rather than a standard competitive maximum. The sponsoring agency is the Centers for Disease Control and Prevention, listed through CDC - ERA (reflecting the electronic research administration system used for submissions and grants management).

Overall, the opportunity is best understood as a targeted continuation of an established CDC-supported CJD blood safety evaluation effort. Its purpose is to continue collecting and analyzing data needed to clarify the real-world risk, if any, of blood-borne transmission for classic CJD forms, using lookback methods and coordinated public health collaboration. The restricted eligibility and continuation structure indicate the primary goal is to sustain an existing, specialized set of partners and workflows rather than launch a new research program.

• The Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Centers for Disease Control and Prevention a Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.084.
• This funding opportunity was created on 2017-02-08.
• Applicants must submit their applications by 2017-04-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Others.

Apply for RFA CK 14 00504CONT17

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: